HomeCompareCDXC vs EQR

CDXC vs EQR: Dividend Comparison 2026

CDXC yields 25.41% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDXC wins by $60.7K in total portfolio value
10 years
CDXC
CDXC
● Live price
25.41%
Share price
$7.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101.2K
Annual income
$11,579.48
Full CDXC calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CDXC vs EQR

📍 CDXC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDXCEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDXC + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDXC pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDXC
Annual income on $10K today (after 15% tax)
$2,160.10/yr
After 10yr DRIP, annual income (after tax)
$9,842.56/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, CDXC beats the other by $6,595.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDXC + EQR for your $10,000?

CDXC: 50%EQR: 50%
100% EQR50/50100% CDXC
Portfolio after 10yr
$70.8K
Annual income
$7,699.54/yr
Blended yield
10.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CDXC
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
11.8
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDXC buys
0
EQR buys
0
No recent congressional trades found for CDXC or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDXCEQR
Forward yield25.41%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$101.2K$40.5K
Annual income after 10y$11,579.48$3,819.61
Total dividends collected$64.5K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: CDXC vs EQR ($10,000, DRIP)

YearCDXC PortfolioCDXC Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$13,241$2,541.30$11,248$547.57+$2.0KCDXC
2$17,313$3,144.86$12,701$666.53+$4.6KCDXC
3$22,368$3,842.92$14,405$814.59+$8.0KCDXC
4$28,574$4,640.12$16,413$999.84+$12.2KCDXC
5$36,114$5,539.72$18,795$1,232.92+$17.3KCDXC
6$45,185$6,543.46$21,639$1,527.95+$23.5KCDXC
7$56,000$7,651.51$25,057$1,903.80+$30.9KCDXC
8$68,782$8,862.44$29,197$2,385.87+$39.6KCDXC
9$83,770$10,173.24$34,250$3,008.70+$49.5KCDXC
10$101,213$11,579.48$40,467$3,819.61+$60.7KCDXC

CDXC vs EQR: Complete Analysis 2026

CDXCStock

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Full CDXC Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CDXC vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDXC vs SCHDCDXC vs JEPICDXC vs OCDXC vs KOCDXC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.